Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Issued (2022 - 2025)

Atara Biotherapeutics' Shares Issued history spans 4 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 83.98% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached $35000.0, down 99.9%, while the annual FY2025 figure was $35000.0, 84.78% down from the prior year.
  • Shares Issued reached -$1.5 million in Q4 2025 per ATRA's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $35.8 million in Q3 2024 to a low of -$9.1 million in Q4 2024.
  • Average Shares Issued over 4 years is $4.6 million, with a median of $1.3 million recorded in 2022.
  • The largest YoY upside for Shares Issued was 1364.69% in 2024 against a maximum downside of 689.78% in 2024.
  • A 4-year view of Shares Issued shows it stood at $1.4 million in 2022, then grew by 12.44% to $1.5 million in 2023, then plummeted by 689.78% to -$9.1 million in 2024, then soared by 83.98% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Shares Issued are -$1.5 million (Q4 2025), $1.5 million (Q3 2025), and -$9.1 million (Q4 2024).